Navigation Links
Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors
Date:9/7/2007

- Adding Bavituximab to Standard Regimen of Androgen Deprivation and Chemotherapy Reduced Size of Formerly Resistant Tumors by More than Half -

- Data Further Confirm Bavituximab's Potential to Enhance Multiple

Combination Regimens for Cancer Therapy -

ATLANTA, and TUSTIN, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported new preclinical studies showing an equivalent of its lead antibody bavituximab significantly shrank resistant human prostate tumors in mice when added to a standard regimen of androgen deprivation and docetaxel. The study findings will be presented today at the Innovative Minds in Prostate Cancer Today (IMPaCT) Conference in Atlanta by Dr. Yi Yin, a post-doctoral fellow in the laboratory of Dr. Philip Thorpe at UT Southwestern Medical Center in Dallas.

"These exciting results mimic the real life situation facing many prostate cancer patients whose disease is failing to respond to the standard combination of androgen deprivation and chemotherapy drugs such as docetaxel," said Dr. Thorpe. "In this study of human prostate tumors in mice, we have shown that administering a bavituximab equivalent significantly enhances the tumors' response to androgen deprivation and docetaxel, with the result that these large resistant tumors shrank by an average of more than 50% over the 13-week study. These findings further strengthen the rationale for use of bavituximab as part of combination therapy regimens for the treatment of prostate cancer."

Prostate cancer is the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Reductions in kidney failure obtained ... people with diabetes type 2 "Intensive treatment ... the kidneys." Australian researchers have discovered that ... leads to persistent reductions in kidney failure many years ... study has found that, five and a half years ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John ... Watch the Video "Congratulations ... campaign trail to earn the trust and votes of the American ... the state of our economy and jobs. "There ...
... HOPKINTON, Mass., Nov. 3, 2010 ... ), a leading provider of tools and services ... announced a collaboration with Sony DADC Austria AG ... for Caliper,s next generation microfluidics products. The agreement ...
Cached Medicine Technology:PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy 2PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy 3Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2
(Date:9/20/2014)... September 21, 2014 Diabetes Protocol ... Pullman that is helping thousands of people learn how ... without shots, pills, or prescriptions has caught the attention ... “There are currently tens of millions of people in ... and Type 2 diabetes, and unfortunately, big pharma makes ...
(Date:9/20/2014)... GA (PRWEB) September 20, 2014 David ... 20, 2014. The first poster looked at the clinical ... cardiac cycle for calculating diastolic function. In conjunction with ... end-stage renal disease and normal LVEF by echo (>50%). ... stress protocol, and standard SPECT. Emory Toolbox 4.0 ...
(Date:9/20/2014)... September 21, 2014 Increases in ... to greater waste treatment volumes. However, government regulations ... waste from landfill. According to IBISWorld industry analyst ... implemented strategies aimed at reducing the volume of ... recycled and recovered.” Still, a large proportion of ...
(Date:9/20/2014)... September 20, 2014 On Monday, September ... $250,000 pediatric cancer research grant from Hyundai Hope on ... University Children’s Hospital located on 11234 Anderson St., in ... Dr. Kimberley Payne, Associate Professor at Loma Linda University ... on leukemia in children. , Loma Linda ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Lifeinsurancequoteterm.net ... advantages a no medical exam life insurance plan provides ... for vulnerable family members should be a top priority ... for life insurance without taking medical examinations and visiting ... not require medical examinations will provide coverage up to ...
Breaking Medicine News(10 mins):Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2
... to see if parents supported the proposal to ban junk ... votes in support//. ,"Ofcom has argued throughout ... advertising would be "disproportionate'," said NHF deputy chief executive Jane ... to the widespread and rising concern about the damage to ...
... pregnancy may be common and those who feel low during ... ,Annette Briley and colleagues from Tommy's Baby Charity here surveyed ... online edition of Daily Mail. ,The survey found ... they felt while being pregnant. Two thirds felt even more ...
... Most expectant parents eagerly wait for the first ultrasound sight of the ... first proof that all is well and the pregnancy is on track. ... of their child until the day of the birth. However this is ... pay hundreds of pounds for a clearer picture of their baby in ...
... the activity of a fat-induced gastrointestinal hormone that promotes ... to researchers at the Texas University Medical Branch at ... Branch at Galveston (UTMB) found the anticancer property of ... and the production of an inflammatory protein that boosts ...
... Administration. has given GlaxoSmithKline PLC's anti-seizure medicine to treat ... ,According to GlaxoSmithKline, the U.K. pharmaceutical company, the ... two and older, as well as adults. ... most-commonly occurring type of generalized seizures, seen in about ...
... Man' clinical trial were given the test drug injections ... monoclonal antibody was TGN 1412 that is supposed to ... have revealed that the victims had been injected 15 ... studies. ,Scientists claim that this 'reckless' mistake ...
Cached Medicine News:Health News:Peek Before Birth 2Health News:Curcumin –New Weapon Against Colorectal Cance 2Health News:Catastrophic Elephant Man Drug Trial Victims Injected Recklessly 2
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
The Manual Table Base is elevated with an easy to reach elevating wheel for smooth operation. The table base will accept a slit lamp, a single table top, or a double tabletop for more than one instru...
A new, innovative design compliments the proven, 30-year mechanical operating system....
The Encore Stand combines the proven mechanical structure and durability of the popular Deluxe Stand, with a modern, sophisticated appearance....
Medicine Products: